Company: CERO
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001213900-25-011071
Chunk: 13

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-02-07
Form: 424B3
Chunk 13
---
able securities to fund our future operating expenses and 
 capital expenditure requirements, including the development and, if approved, commercialization of our product candidates;          |

| ● | our ability to realize                                                                              
 the benefits expected from the Business Combination pursuant to the Business Combination Agreement; |

| ● | successfully defend litigation                                                 
 that may be instituted against us in connection with the Business Combination; |

| ● | the accuracy of our estimates                                                                 
 regarding expenses, future revenue, capital requirements, and needs for additional financing; |

| ● | the scope, progress, results                                                                                                     
 and costs of developing CER-1236 or any other product candidates we may develop, and conducting preclinical studies and clinical 
 trials;                                                                                                                          |

| ● | the timing and costs involved                                                                                                             
 in obtaining and maintaining regulatory approval of CER-1236 or any other product candidates we may develop, and the timing or likelihood 
 of regulatory filings and approvals, including our expectation to seek special designations or accelerated approvals for our drug         
 candidates for various indications;                                                                                                       |

| ● | current and future agreements                                                                                                  
 with third parties in connection with the development and commercialization of CER-1236 or any other future product candidate; |

| ● | our ability to advance                                             
 product candidates into and successfully complete clinical trials; |

| ● | the ability of our clinical                                                                                                            
 trials to demonstrate the safety and efficacy of CER-1236 and any other product candidates we may develop, and other positive results; |

| ● | the size and growth potential                                                      
 of the markets for our product candidates, and our ability to serve those markets; |

| ● | the rate and degree of                       
 market acceptance of our product candidates; |

| ● | our plans relating to commercializing                                                                                             
 CER-1236 and any other product candidates we may develop, if approved, including the geographic areas of focus and our ability to 
 grow a sales team;                                                                                                                |

| ● | the success of competing drugs, therapies or other 
 products that are or may become available;         |

<div align='center'>x</div>

| ● | developments relating to                                                                
 our competitors and our industry, including competing product candidates and therapies; |

| ● | our plans relating to the                                                                                                           
 further development and manufacturing of CER-1236 and any other product candidates we may develop, including additional indications 
 that we may pursue for CER-1236 or other product candidates;                                                                        |

| ● | existing regulations and                                              
 regulatory developments in